Longitudinal live imaging of retinal α-synuclein::GFP deposits in a transgenic mouse model of Parkinson's Disease/Dementia with Lewy Bodies

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Price, Diana L ^a   Rockenstein, Edward ^b   Mante, Michael ^b   Adame, Anthony ^b   Overk, Cassia ^b   Spencer, Brian ^b   Duong Polk, Karen X ^c   Bonhaus, Douglas ^a   Lindsey, James ^c   Masliah, Eliezer ^b,d  

^a Neuropore Therapies   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; FUSION PROTEIN; GREEN FLUORESCENT PROTEIN; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY;

ANIMAL; DEVICES; DIAGNOSTIC IMAGING; DIFFUSE LEWY BODY DISEASE; DISEASE EXACERBATION; DISEASE MODEL; DRUG EFFECT; FLUORESCENCE IMAGING; GENETICS; HUMAN; IMMUNOTHERAPY; MALE; METABOLISM; MOUSE; PARKINSON DISEASE; RETINA; RETINA GANGLION CELL; TRANSGENIC MOUSE;

ALPHA-SYNUCLEIN; ANIMALS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; GREEN FLUORESCENT PROTEINS; HUMANS; IMMUNOTHERAPY; LEWY BODY DISEASE; MALE; MICE; MICE, TRANSGENIC; OPTICAL IMAGING; PARKINSON DISEASE; RECOMBINANT FUSION PROTEINS; RETINA; RETINAL GANGLION CELLS; SINGLE-CHAIN ANTIBODIES;

EID: 84978141436     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep29523     Document Type: Article

References (47)

1. Scott, D. A. et al. A pathologic cascade leading to synaptic dysfunction in alpha-synuclein-induced neurodegeneration. J Neurosci 30, 8083-8095, doi: 10.1523/JNEUROSCI.1091-10.2010 (2010)
2. Lashuel, H. A., Overk, C. R., Oueslati, A. & Masliah, E. The many faces of alpha-synuclein: from structure and toxicity to therapeutic target. Nat Rev Neurosci 14, 38-48, doi: 10.1038/nrn3406 (2013)
3. Halliday, G. M., Holton, J. L., Revesz, T. & Dickson, D. W. Neuropathology underlying clinical variability in patients with synucleinopathies. Acta Neuropathol 122, 187-204, doi: 10.1007/s00401-011-0852-9 (2011)
4. Irwin, D. J., Lee, V. M. & Trojanowski, J. Q. Parkinsons disease dementia: convergence of alpha-synuclein, tau and amyloid-beta pathologies. Nature reviews. Neuroscience 14, 626-636, doi: 10.1038/nrn3549 (2013)
5. McKeith, I. G. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the Consortium on DLB International Workshop. J Alzheimers Dis 9, 417-423 (2006)
6. Chesselet, M. F. & Richter, F. Modelling of Parkinsons disease in mice. Lancet Neurol 10, 1108-1118, doi: 10.1016/S1474- 4422(11)70227-7 (2011)
7. Wang, L., Fleming, S. M., Chesselet, M. F. & Tache, Y. Abnormal colonic motility in mice overexpressing human wild-type alphasynuclein. Neuroreport 19, 873-876, doi: 10.1097/WNR.0b013e3282ffda5e [doi] 00001756-200805280-00016 [pii] (2008)
8. Fleming, S. M. et al. Olfactory deficits in mice overexpressing human wildtype alpha-synuclein. Eur J Neurosci 28, 247-256, doi: 10.1111/j.1460-9568.2008.06346.x (2008)
9. Fleming, S. M. et al. Impaired baroreflex function in mice overexpressing alpha-synuclein. Front Neurol 4, 103, doi: 10.3389/ fneur.2013.00103 (2013)
10. Kudo, T., Loh, D. H., Truong, D., Wu, Y. & Colwell, C. S. Circadian dysfunction in a mouse model of Parkinsons disease. Exp Neurol 232, 66-75, doi: 10.1016/j.expneurol.2011.08.003 (2011)
11. Beach, T. G. et al. Phosphorylated alpha-synuclein-immunoreactive retinal neuronal elements in Parkinsons disease subjects. Neuroscience letters 571, 34-38, doi: 10.1016/j.neulet.2014.04.027 (2014)
12. Bodis-Wollner, I., Kozlowski, P. B., Glazman, S. & Miri, S. alpha-synuclein in the inner retina in parkinson disease. Ann Neurol 75, 964-966, doi: 10.1002/ana.24182 (2014)
13. Tofaris, G. K. et al. Pathological changes in dopaminergic nerve cells of the substantia nigra and olfactory bulb in mice transgenic for truncated human alpha-synuclein(1-120): implications for Lewy body disorders. J Neurosci 26, 3942-3950, doi: 10.1523/ JNEUROSCI.4965-05.2006 (2006)
14. Shannon, K. M. et al. Alpha-synuclein in colonic submucosa in early untreated Parkinsons disease. Mov. Disord. 27, 709-715, doi: 10.1002/mds.23838 (2012)
15. Wakabayashi, K., Takahashi, H., Ohama, E. & Ikuta, F. Parkinsons disease: an immunohistochemical study of Lewy body-containing neurons in the enteric nervous system. Acta Neuropathol 79, 581-583 (1990)
16. Michell, A. W., Luheshi, L. M. & Barker, R. A. Skin and platelet alpha-synuclein as peripheral biomarkers of Parkinsons disease. Neuroscience letters 381, 294-298, doi: 10.1016/j.neulet.2005.02.030 (2005)
17. Orimo, S. et al. Axonal alpha-synuclein aggregates herald centripetal degeneration of cardiac sympathetic nerve in Parkinsons disease. Brain 131, 642-650, doi: 10.1093/brain/awm302 (2008)
18. Adler, C. H. et al. Submandibular gland needle biopsy for the diagnosis of Parkinson disease. Neurology 82, 858-864, doi: 10.1212/ WNL.0000000000000204 (2014)
19. Inzelberg, R., Ramirez, J. A., Nisipeanu, P. & Ophir, A. Retinal nerve fiber layer thinning in Parkinson disease. Vision Res 44, 2793-2797, doi: 10.1016/j.visres.2004.06.009 (2004)
20. Altintas, O., Iseri, P., Ozkan, B. & Caglar, Y. Correlation between retinal morphological and functional findings and clinical severity in Parkinsons disease. Doc Ophthalmol 116, 137-146, doi: 10.1007/s10633-007-9091-8 (2008)
21. Frost, S. et al. Retinal vascular biomarkers for early detection and monitoring of Alzheimers disease. Transl Psychiatry 3, e233, doi: 10.1038/tp.2012.150 (2013)
22. Parnell, M., Guo, L., Abdi, M. & Cordeiro, M. F. Ocular manifestations of Alzheimers disease in animal models. Int J Alzheimers Dis 786494, doi: 10.1155/2012/786494 (2012)
23. Chiu, K et al. Neurodegeneration of the retina in mouse models of Alzheimers disease: what can we learn from the retina? Age (Dordr) 34, 633-649, doi: 10.1007/s11357-011-9260-2 (2012)
24. Koronyo, Y., Salumbides, B. C., Black, K. L. & Koronyo-Hamaoui, M. Alzheimers disease in the retina: imaging retinal abeta plaques for early diagnosis and therapy assessment. Neuro-degenerative diseases 10, 285-293, doi: 10.1159/000335154 (2012)
25. Park, S. W. et al. A selective inhibitor of drp1, mdivi-1, increases retinal ganglion cell survival in acute ischemic mouse retina. Investigative ophthalmology & visual science 52, 2837-2843, doi: 10.1167/iovs.09-5010 (2011)
26. Rockenstein, E. et al. Lysosomal pathology associated with alpha-synuclein accumulation in transgenic models using an eGFP fusion protein. J Neurosci Res 80, 247-259 (2005)
27. Unni, V. K. et al. In vivo imaging of alpha-synuclein in mouse cortex demonstrates stable expression and differential subcellular compartment mobility. PLoS One 5, e10589, doi: 10.1371/journal.pone.0010589 (2010)
28. Spinelli, K. J. et al. Presynaptic alpha-synuclein aggregation in a mouse model of Parkinsons disease. J Neurosci 34, 2037-2050, doi: 10.1523/JNEUROSCI.2581-13.2014 (2014)
29. Spencer, B. et al. Lentivirus mediated delivery of neurosin promotes clearance of wild-type alpha-synuclein and reduces the pathology in an alpha-synuclein model of LBD. Mol Ther 21, 31-41, doi: 10.1038/mt.2012.66 (2013)
30. Ivanova, E., Toychiev, A. H., Yee, C. W. & Sagdullaev, B. T. Optimized protocol for retinal wholemount preparation for imaging and immunohistochemistry. J Vis Exp. e51018, doi: 10.3791/51018 (2013)
31. Spencer, B. et al. ESCRT-mediated uptake and degradation of brain-targeted alpha-synuclein single chain antibody attenuates neuronal degeneration in vivo. Mol Ther 22, 1753-1767, doi: 10.1038/mt.2014.129 (2014)
32. Valera, E. & Masliah, E. Immunotherapy for neurodegenerative diseases: focus on alpha-synucleinopathies. Pharmacology & therapeutics 138, 311-322, doi: 10.1016/j.pharmthera.2013.01.013 (2013)
33. Surguchov, A., McMahan, B., Masliah, E. & Surgucheva, I. Synucleins in ocular tissues. J Neurosci Res 65, 68-77 (2001)
34. Chen, L. & Feany, M. B. Alpha-synuclein phosphorylation controls neurotoxicity and inclusion formation in a Drosophila model of Parkinson disease. Nat Neurosci 8, 657-663 (2005)
35. Roy, B. & Jackson, G. R. Interactions between Tau and alpha-synuclein augment neurotoxicity in a Drosophila model of Parkinsons disease. Hum Mol Genet 23, 3008-3023, doi: 10.1093/hmg/ddu011 (2014)
36. Scott, D. A. et al. A pathologic cascade leading to synaptic dysfunction in alpha-synuclein-induced neurodegeneration. J Neurosci 30, 8083-8095, doi: 10.1523/JNEUROSCI.1091-10.2010 (2010)
37. Rockenstein, E., Crews, L. & Masliah, E. Transgenic animal models of neurodegenerative diseases and their application to treatment development. Adv Drug Deliv Rev 59, 1093-1102 (2007)
38. Jellinger, K. A. Synuclein deposition and non-motor symptoms in Parkinson disease. Journal of the neurological sciences 310, 107-111, doi: 10.1016/j.jns.2011.04.012 (2011)
39. Maurage, C. A., Ruchoux, M. M., de Vos, R., Surguchov, A. & Destee, A. Retinal involvement in dementia with Lewy bodies: a clue to hallucinations? Ann Neurol 54, 542-547, doi: 10.1002/ana.10730 (2003)
40. Leger, F. et al. Protein aggregation in the aging retina. J Neuropath Exp Neurol 70, 63-68, doi: 10.1097/NEN.0b013e31820376cc (2011)
41. Ho, C. Y., Troncoso, J. C., Knox, D., Stark, W. & Eberhart, C. G. Beta-amyloid, phospho-tau and alpha-synuclein deposits similar to those in the brain are not identified in the eyes of Alzheimers and Parkinsons disease patients. Brain Pathol 24, 25-32, doi: 10.1111/ bpa.12070 (2014)
42. Tamo, W. et al. Expression of alpha-synuclein, the precursor of non-amyloid beta component of Alzheimers disease amyloid, in human cerebral blood vessels. Neuroscience letters 326, 5-8 (2002)
43. Merlini, M., Wanner, D. & Nitsch, R. M. Tau pathology-dependent remodelling of cerebral arteries precedes Alzheimers diseaserelated microvascular cerebral amyloid angiopathy. Acta Neuropathol 131, 737-752, doi: 10.1007/s00401-016-1560-2 (2016)
44. Surgucheva, I. et al. Synucleins in glaucoma: implication of gamma-synuclein in glaucomatous alterations in the optic nerve. J Neurosci Res 68, 97-106 (2002)
45. Surgucheva, I., Weisman, A. D., Goldberg, J. L., Shnyra, A. & Surguchov, A. Gamma-synuclein as a marker of retinal ganglion cells. Molecular vision 14, 1540-1548 (2008)
46. Martinez-Navarrete, G. C., Martin-Nieto, J., Esteve-Rudd, J., Angulo, A. & Cuenca, N. Alpha synuclein gene expression profile in the retina of vertebrates. Molecular vision 13, 949-961 (2007)
47. Koronyo-Hamaoui, M. et al. Identification of amyloid plaques in retinas from Alzheimers patients and noninvasive in vivo optical imaging of retinal plaques in a mouse model. NeuroImage 54 Suppl 1, S204-S217, doi: 10.1016/j.neuroimage.2010.06.020 (2011)